3977 — Fusion Co Share News
0.000.00%
Last trade - 00:00Table: Fusion -2025/26 parent forecast
Table: Fusion - 9-MTH parent results
Table: Fusion - 6-MTH parent results
2025 6-month parent forecast
Table: Fusion - Q1 parent results
Table: Fusion -2024/25 parent results
Table: Fusion -2024/25 parent forecast
Table: Fusion - 9-MTH parent results
2024 6-month parent forecast
Table: Fusion - Q1 parent results
Table: Fusion -2023/24 parent forecast
Table: Fusion -2023/24 parent results
Brief: Astrazeneca To Acquire Fusion To Accelerate The Development Of Next-Generation Radioconjugates To Treat Cancer
Table: Fusion - 9-MTH parent results
2023 6-month group forecast
Table: Fusion - 6-MTH parent results
Table: Fusion - Q1 parent results
Table: Fusion -2022/23 parent results
Table: Fusion -2022/23 parent forecast